Underwriters over-allotment is an additional 675,000 shares.
Net proceeds will be used to fund the development of its pipeline of gene therapies for rare diseases, to accelerate the buildout of in-house manufacturing capabilities, and for general corporate purposes.
Closing date is April 18.
Previously: Rocket Pharma down 5% after hours on equity offering (April 15)
Subscribe for full text news in your inbox